Prolia (Denosumab) Cannabis Interaction Profile

How Denosumab Is Processed in the Body

Denosumab is a fully human IgG2 monoclonal antibody. It does not pass through the liver's cytochrome P450 (CYP450) system the way small-molecule drugs do. The body clears it through the same proteolytic pathways it uses to clear endogenous immunoglobulins, meaning the kidneys, CYP2D6, CYP3A4, and related enzymes are not involved.

This distinction matters for understanding cannabis interactions. Many drug-cannabis interactions occur because delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both inhibit and induce specific CYP enzymes. CBD is a potent inhibitor of CYP3A4 and CYP2C9 at clinically relevant doses. THC is a moderate CYP3A4 substrate. Because denosumab bypasses this system entirely, those enzyme-based collisions do not apply here.

The FDA label for Prolia states: "No formal drug interaction studies have been conducted with PROLIA." [1] That sentence reflects the low priority placed on CYP-based interaction testing for biologics, not a gap in safety data.

Protein Binding and Distribution

Denosumab has a half-life of approximately 26 days and reaches peak serum concentration roughly 10 days after a subcutaneous injection. It binds RANKL (receptor activator of nuclear factor kappa-B ligand) with very high affinity (Kd approximately 3 x 10-12 M). THC is highly lipophilic and protein-bound, but competition for plasma protein binding sites between a large glycoprotein antibody and a small lipophilic molecule is not a clinically meaningful mechanism.

Clearance Pathway Summary

| Pathway | Denosumab | THC | CBD | |---|---|---|---| | CYP3A4 | Not a substrate | Substrate | Inhibitor | | CYP2C9 | Not a substrate | Minor substrate | Inhibitor | | CYP2D6 | Not a substrate | Not a substrate | Minor inhibitor | | Proteolysis | Primary clearance | Not applicable | Not applicable | | Renal excretion | Minimal | Minimal | Minimal |

Cannabis Effects on Bone: The Independent Risk You Should Know

Even without a direct drug-drug interaction, cannabis use in patients receiving denosumab for osteoporosis deserves attention. The endocannabinoid system is active in bone metabolism, and the net effect of cannabis exposure on bone mineral density (BMD) is not benign.

CB1 and CB2 Receptors in Bone

CB1 and CB2 receptors are expressed on osteoblasts, osteoclasts, and osteocytes. A 2006 study in the Journal of Clinical Investigation by Ofek et al. Showed that CB2-deficient mice developed age-related osteoporosis, and pharmacological CB2 activation reduced osteoclast activity in that model. [2] That suggests a possible protective role for CB2 signaling in bone.

The problem is that cannabis does not selectively activate CB2. THC binds both CB1 and CB2, and CB1 activation on sympathetic nerve terminals has been linked to increased bone resorption in animal models. The net human effect appears to depend heavily on frequency, dose, and age of first use.

Human Observational Data

A cross-sectional analysis using NHANES data (N=4,500+) found that current cannabis users had lower femoral neck BMD compared with never-users after adjusting for tobacco, alcohol, and physical activity. The association was strongest in men under 50. [3] A separate prospective cohort study published in the American Journal of Medicine (N=1,963 adults followed over 5 years) found that heavy cannabis use (more than 5 days per week) was associated with a 3.7% lower lumbar spine BMD compared to non-users, though light use showed no statistically significant difference. [4]

These numbers matter because denosumab is prescribed specifically to people whose BMD is already compromised. A therapy gaining 2-4% in lumbar spine BMD per year (the typical response seen in the FREEDOM trial) should not be offset by a modifiable behavior reducing BMD by a similar magnitude. [5]

Smoking Route Adds Additional Risk

Cannabis smoked by combustion carries carbon monoxide and respiratory irritants that reduce tissue oxygenation. Low oxygenation at the bone surface impairs osteoblast activity. Tobacco smoking is an established independent risk factor for osteoporosis, and while the data on smoked cannabis are less mature, the FREEDOM trial and subsequent extension studies did not permit heavy smoking of any kind during enrollment. [5]

Vaporized or oral cannabis avoids combustion products. If a patient insists on continuing cannabis use during Prolia therapy, switching to a non-combustion route reduces, but does not eliminate, the bone metabolism concern.

Immune System Considerations

Denosumab has known immunomodulatory effects. The FREEDOM trial (N=7,808) reported that serious infections occurred in 4.1% of denosumab patients versus 3.4% of placebo patients at 36 months, a difference that became more notable in post-marketing data, particularly for cellulitis and endocarditis. [5] The FDA label includes a warning for serious infections. [1]

Cannabis is also immunomodulatory. THC suppresses T-cell proliferation, reduces natural killer cell activity, and shifts cytokine profiles toward anti-inflammatory patterns, which sounds beneficial in isolation but can blunt the immune surveillance needed to prevent opportunistic infections.

Additive Immunosuppression Risk

No trial has directly measured combined denosumab-plus-cannabis infection risk. Based on the known mechanisms, the concern is biologically plausible rather than statistically proven. Patients with diabetes, chronic corticosteroid use, or other immunosuppressive conditions are already flagged for heightened infection monitoring on denosumab. Regular heavy cannabis use should be added to that clinical picture.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in men notes that practitioners should review all substances affecting immune function before initiating RANKL inhibitor therapy. [6]

Oral Health Overlap

Osteonecrosis of the jaw (ONJ) is a rare but serious denosumab adverse effect. Cannabis users who smoke have higher rates of periodontal disease and gingival inflammation. Periodontal infection is a documented trigger for ONJ in patients on RANKL inhibitors. [7] Patients should maintain excellent dental hygiene regardless of cannabis use, but smokers have an additional structural reason to address dental health before and during Prolia therapy.

Hypocalcemia: Cannabis Does Not Change the Math, But Nutrition Does

Denosumab's most common serious adverse effect is hypocalcemia, occurring in roughly 9.6% of patients in the FREEDOM extension, with severe cases (serum calcium <7.5 mg/dL) more frequent in patients with vitamin D insufficiency. [8] The Prolia label requires that all patients receive at least 1,000 mg of calcium and 400 IU of vitamin D daily. [1]

Cannabis does not directly alter calcium homeostasis or PTH secretion in healthy adults based on available data. However, cannabis-associated appetite changes, nausea (particularly in cannabinoid hyperemesis syndrome), or dietary neglect can reduce dietary calcium intake. Poor dietary calcium intake on top of inadequate supplementation can compound denosumab-induced hypocalcemia risk.

Patients who use cannabis for chemotherapy-related nausea (a common off-label use) may have pre-existing nutritional deficits that require more aggressive calcium and vitamin D repletion before starting denosumab.

Alcohol and Denosumab: A Separate Question Worth Addressing

Many patients who ask about cannabis also ask about alcohol. The clinical picture for alcohol is cleaner and more firmly established.

Chronic alcohol consumption is a well-documented independent risk factor for osteoporosis. Meta-analysis data from 33 studies (N=198,752) published in Osteoporosis International found that alcohol intake above 2 units per day was associated with a 28% higher hip fracture risk. [9] Alcohol suppresses osteoblast function, interferes with calcium absorption, reduces 25-hydroxyvitamin D levels, and elevates parathyroid hormone.

Like cannabis, alcohol does not share CYP450 clearance pathways with denosumab in a clinically meaningful way. Alcohol is metabolized primarily by alcohol dehydrogenase and CYP2E1. Denosumab does not interact with either. So the interaction is pharmacodynamic rather than pharmacokinetic: both alcohol and undertreated osteoporosis increase fracture risk, and denosumab's protective benefit may be partially offset by ongoing heavy drinking.

The practical recommendation from the National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) is to limit alcohol to no more than 2-3 units per day. [10] There is no absolute contraindication to moderate alcohol during Prolia therapy, but patients should understand that fracture risk reduction from denosumab is maximized when modifiable lifestyle factors are controlled.

Cannabidiol (CBD) as a Specific Case

CBD products are increasingly available and many patients self-administer them without disclosing use to prescribers. CBD is not a controlled substance at the federal level in the same way THC is, and patients may not think to mention it.

CBD at doses above 300 mg per day produces measurable CYP3A4 and CYP2C9 inhibition. For most small-molecule drugs metabolized by those enzymes (warfarin, clobazam, sirolimus), this inhibition is clinically significant. For denosumab, it is not, for the pharmacokinetic reasons described above.

However, high-dose CBD (the doses used in the Epidiolex clinical trials, 10-20 mg/kg/day) has been associated with elevated liver enzymes (ALT greater than 3x upper limit of normal in roughly 5-20% of patients). [11] Denosumab is not hepatotoxic on its own, but co-administration of any hepatotoxic agent in a patient who may also be on alendronate (if switching agents) or on concurrent medications warrants liver function awareness.

Over-the-Counter CBD Dose Reality

Most OTC CBD products contain 25-100 mg per serving. At those doses, CYP inhibition is minimal and hepatotoxicity risk is very low. The liver enzyme signal described above is specific to high-dose pharmaceutical CBD, not to typical consumer products. Patients using standard-dose CBD gummies or tinctures while on Prolia have no well-documented interaction risk.

Clinical Decision Framework: How to Manage a Prolia Patient Who Uses Cannabis

The following framework reflects the HealthRX medical team's approach for patients disclosing cannabis use during Prolia therapy or at initiation.

Step 1. Quantify use. Frequency (days per week), dose (approximate grams or milligrams of THC/CBD), and route (smoked, vaped, oral). Heavy use is defined as more than 5 days per week or more than 1 gram of flower per day.

Step 2. Assess baseline BMD. If the most recent DEXA shows T-score worse than -2.5 at any site, the pharmacodynamic interference from cannabis on bone formation becomes more clinically significant. Document the starting T-score to allow year-1 DEXA comparison.

Step 3. Check calcium and vitamin D status. Order serum 25-OH vitamin D and a comprehensive metabolic panel (including corrected serum calcium) at baseline and at 2-4 weeks post-injection. Cannabis-related dietary irregularity increases hypocalcemia risk if supplementation is inconsistent.

Step 4. Dental evaluation. Refer to dentistry before first Prolia injection if the patient smokes cannabis. Periodontal disease should be treated before therapy starts.

Step 5. Infection surveillance. Add regular cannabis use to the list of factors elevating infection risk. Counsel patients on the cellulitis warning signs described in the Prolia prescribing information.

Step 6. Reassess at 6-month injection visit. Review BMD trajectory at the 12-month DEXA. If BMD gain is below expected (less than 2% at lumbar spine at year 1), quantify cannabis use changes and address other modifiable factors before attributing inadequate response solely to denosumab dosing.

What Patients Should Tell Their Prescriber

Patients often do not disclose cannabis use because they assume it is irrelevant to bone medications or because they fear judgment. The scientific reality is that prescribers need to know:

1. Whether cannabis use is smoked (periodontal and osteonecrosis of jaw risk)
2. Whether it is daily or near-daily (independent BMD suppression risk)
3. Whether high-dose CBD is being used concurrently with other CYP-metabolized drugs (not a denosumab issue, but may affect co-prescriptions)
4. Whether cannabis is being used as an appetite stimulant or antiemetic (nutritional adequacy affects calcium supplementation success)

The American Society for Bone and Mineral Research 2022 guidelines on secondary osteoporosis contributors specifically include substance use assessment as part of pre-treatment workup. [12]

Monitoring Parameters During Combined Use

Patients using cannabis regularly while on Prolia should expect the following monitoring schedule:

• Serum calcium and vitamin D: at baseline, 2-4 weeks after each injection, and any time symptoms of hypocalcemia appear (perioral tingling, muscle cramps, Chvostek sign)
• DEXA scan: at 1-2 years after starting therapy, then every 2 years if response is adequate
• Dental examination: every 6 months
• Infection review: at every clinical encounter; any dental procedure requiring invasive work should be discussed with the Prolia prescriber before proceeding

A serum 25-OH vitamin D level of 30 ng/mL or above is the target threshold recommended in the Prolia label before and during therapy. [1] Cannabis does not directly deplete vitamin D, but patients with cannabis-associated dietary irregularity should have this level checked more frequently than the standard annual screen.